CYP2D6 and CYP2C19 genotype‐based dose recommendations for antidepressants:
a first step towards subpopulation‐specific dosages

Objective: This review aimed to provide distinct dose recommendations for antidepressants based on the genotypes of cytochrome P450 enzymes CYP2D6 and CYP2C19. This approach may be a useful complementation to clinical monitoring and therapeutic drug monitoring.

[1]  Clomipramine dose‐effect study in patients with depression: Clinical end points and pharmacokinetics , 1999, Clinical pharmacology and therapeutics.

[2]  C. Alm,et al.  Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2 activity , 1996, Clinical pharmacology and therapeutics.

[3]  C. Hiemke,et al.  The role of cytochrome P450 2D6 in the metabolism of moclobemide , 1996, European Neuropsychopharmacology.

[4]  T Ishizaki,et al.  Genotyping of S‐mephenytoin 4′‐hydroxylation in an extended Japanese population , 1996, Clinical pharmacology and therapeutics.

[5]  L. Bertilsson,et al.  Genetically variable metabolism of antidepressants and neuroleptic drugs in man. , 1993, Pharmacogenetics.

[6]  E. Griesser,et al.  Biotransformation of moclobemide in humans , 1990, Acta psychiatrica Scandinavica. Supplementum.

[7]  P. Beaune,et al.  Major pathway of imipramine metabolism is catalyzed by cytochromes P-450 1A2 and P-450 3A4 in human liver. , 1993, Molecular pharmacology.

[8]  M Schwab,et al.  Elucidation of the genetic basis of the common 'intermediate metabolizer' phenotype for drug oxidation by CYP2D6. , 2000, Pharmacogenetics.

[9]  M. Scheinin,et al.  Disposition of single oral doses of E‐10‐hydroxynortriptyline in healthy subjects, with some observations on pharmacodynamic effects , 1986, Clinical pharmacology and therapeutics.

[10]  T. Cooper,et al.  Determination of trimipramine and metabolites in plasma by liquid chromatography with electrochemical detection. , 1984, Journal of Pharmacy and Science.

[11]  M. Dahl,et al.  Pharmacogenetics of antidepressants: clinical aspects , 1997, Acta psychiatrica Scandinavica. Supplementum.

[12]  L. Bertilsson,et al.  Pronounced inhibition of noradrenaline uptake by 10-hydroxymetabolites of nortriptyline. , 1979, Life sciences.

[13]  D. Greenblatt,et al.  O- and N-demethylation of Venlafaxine In Vitro by Human Liver Microsomes and by Microsomes from cDNA-Transfected Cells: Effect of Metabolic Inhibitors and SSRI Antidepressants , 1999, Neuropsychopharmacology.

[14]  B. Mellström,et al.  Phenotypic consistency in hydroxylation of desmethylimipramine and debrisoquine in healthy subjects and in human liver microsomes , 1984, Clinical pharmacology and therapeutics.

[15]  J. Brockmöller,et al.  Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. , 1997, American journal of human genetics.

[16]  R. Barbhaiya,et al.  Clinical Pharmacokinetics of Nefazodone , 1997, Clinical pharmacokinetics.

[17]  G R Wilkinson,et al.  The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. , 1994, The Journal of biological chemistry.

[18]  L. Bertilsson,et al.  Interethnic factors affecting drug response , 1994 .

[19]  C. Eap,et al.  Steady state plasma levels of the enantiomers of trimipramine and of its metabolites in CYP2D6-, CYP2C19- and CYP3A4/5-phenotyped patients. , 2000, Therapeutic drug monitoring.

[20]  C. Bye,et al.  Paroxetine plasma levels: lack of correlation with efficacy or adverse events , 1989, Acta psychiatrica Scandinavica. Supplementum.

[21]  O. Spigset,et al.  Lack of correlation between fluvoxamine clearance and CYP1A2 activity as measured by systemic caffeine clearance , 1999, European Journal of Clinical Pharmacology.

[22]  L. Gram,et al.  Plasma Level Monitoring of Tricyclic Antidepressant Therapy , 1977, Clinical pharmacokinetics.

[23]  R. Blouin,et al.  Comparison of the pharmacokinetics of moclobemide in poor and efficient metabolizers of debrisoquine , 1990, Acta psychiatrica Scandinavica. Supplementum.

[24]  D. Greenblatt,et al.  Five Distinct Human Cytochromes Mediate Amitriptyline N‐Demethylation In Vitro: Dominance of CYP 2C19 and 3A4 , 1998, Journal of clinical pharmacology.

[25]  S. Preskorn.  Pharmacokinetics of antidepressants: why and how they are relevant to treatment. , 1993, The Journal of clinical psychiatry.

[26]  K. Brøsen,et al.  Imipramine metabolism in relation to the sparteine oxidation polymorphism--a family study. , 1996, Pharmacogenetics.

[27]  L. Bertilsson,et al.  Plasma concentrations of nortriptyline and its 10-hydroxy metabolite in depressed patients--relationship to the debrisoquine hydroxylation metabolic ratio. , 1985, British journal of clinical pharmacology.

[28]  J. Haskins,et al.  Biochemical, neurophysiological, and behavioral effects of Wy‐45,233 and other identified metabolites of the antidepressant venlafaxine , 1991 .

[29]  Harold I. Kaplan,et al.  Synopsis of psychiatry: Behavioral sciences : clinical psychiatry , 1988 .

[30]  M. Ingelman-Sundberg,et al.  Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[31]  B. Pollock,et al.  Newer antidepressants and the cytochrome P450 system. , 1996, The American journal of psychiatry.

[32]  K. Otani,et al.  Effects of carbamazepine coadministration on plasma concentrations of trazodone and its active metabolite, m-chlorophenylpiperazine. , 1996, Therapeutic drug monitoring.

[33]  O. Spigset,et al.  Effect of cigarette smoking on fluvoxamine pharmacokinetics in humans , 1995, Clinical pharmacology and therapeutics.

[34]  D. Pessayre,et al.  Metabolic activation of the new tricyclic antidepressant tianeptine by human liver cytochrome P450. , 1990, Biochemical pharmacology.

[35]  E. Steiner,et al.  Differences in the inhibitory effect of cimetidine on desipramine metabolism between rapid and slow debrisoquin hydroxylators , 1987, Clinical pharmacology and therapeutics.

[36]  Kaoru Kobayashi,et al.  Sertraline N-demethylation is catalyzed by multiple isoforms of human cytochrome P-450 in vitro. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[37]  F. Sjöqvist,et al.  Plasma levels of monomethylated tricyclic antidepressants during treatment with imipramine-like compounds. , 1967, Life sciences.

[38]  J. Idle,et al.  POLYMORPHIC HYDROXYLATION OF DEBRISOQUINE IN MAN , 1977, The Lancet.

[39]  P. Baumann,et al.  Amitriptyline pharmacokinetics and clinical response: II. Metabolic polymorphism assessed by hydroxylation of debrisoquine and mephenytoin. , 1986, International clinical psychopharmacology.

[40]  C. Nemeroff,et al.  New antidepressants and the cytochrome P450 system: Focus on venlafaxine, nefazodone, and mirtazapine , 1998, Depression and anxiety.

[41]  L. Bertilsson,et al.  Active Hydroxymetabolites of Antidepressants , 1995, Clinical pharmacokinetics.

[42]  R. Dahlqvist,et al.  Inhibition of desipramine 2-hydroxylation by quinidine and quinine in rapid and slow debrisoquine hydroxylators. , 1989, Psychopharmacology series.

[43]  I. Poggesi,et al.  Review of the pharmacokinetics and metabolism of reboxetine, a selective noradrenaline reuptake inhibitor , 1997, European Neuropsychopharmacology.

[44]  D. Wong,et al.  Fluoxetine and its two enantiomers as selective serotonin uptake inhibitors. , 1990, Acta pharmaceutica Nordica.

[45]  L. Bertilsson,et al.  Pharmacokinetics of nortriptyline and its 10‐hydroxy metabolite in Chinese subjects of different CYP2D6 genotypes , 1998, Clinical pharmacology and therapeutics.

[46]  O. Spigset,et al.  Relationship between fluvoxamine pharmacokinetics and CYP2D6/CYP2C19 phenotype polymorphisms , 1997, European Journal of Clinical Pharmacology.

[47]  A. Bozkurt,et al.  Low frequency of defective alleles of cytochrome P450 enzymes 2C19 and 2D6 in the Turkish population , 1999, Clinical pharmacology and therapeutics.

[48]  Tricyclic antidepressants--blood level measurements and clinical outcome: an APA Task Force report. Task Force on the Use of Laboratory Tests in Psychiatry. , 1985, The American journal of psychiatry.

[49]  M. S. Ching,et al.  Role of cytochrome P450 2D6 (CYP2D6) in the stereospecific metabolism of E- and Z-doxepin. , 2000, Pharmacogenetics.

[50]  S. Ekins,et al.  Three-dimensional quantitative structure activity relationship analyses of substrates for CYP2B6. , 1999, The Journal of pharmacology and experimental therapeutics.

[51]  S. Otton,et al.  Imipramine demethylation and hydroxylation: Impact of the sparteine oxidation phenotype , 1986, Clinical pharmacology and therapeutics.

[52]  M. Ingelman-Sundberg,et al.  Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine , 1993, The Lancet.

[53]  L. Bertilsson,et al.  10‐hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes , 1998, Clinical pharmacology and therapeutics.

[54]  R. Blouin,et al.  The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: Screening costs and influence on clinical outcomes in psychiatry , 1996, Clinical pharmacology and therapeutics.

[55]  B. Mellström,et al.  Demethylation and hydroxylation of amitriptyline, nortriptyline, and 10-hydroxyamitriptyline in human liver microsomes. , 1981, Drug metabolism and disposition: the biological fate of chemicals.

[56]  L. Bertilsson,et al.  Geographical/Interracial Differences in Polymorphic Drug Oxidation , 1995, Clinical pharmacokinetics.

[57]  E. Skjelbo,et al.  The N-demethylation of imipramine correlates with the oxidation of S-mephenytoin (S/R-ratio). A population study. , 1993, British journal of clinical pharmacology.

[58]  L. Bertilsson,et al.  Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype. , 1995, Pharmacogenetics.

[59]  S. Stahl,et al.  Mirtazapine: An Antidepressant with Noradrenergic and Specific Serotonergic Effects , 1997, Pharmacotherapy.

[60]  O. Spigset,et al.  Non-linear fluvoxamine disposition. , 1998, British journal of clinical pharmacology.

[61]  U. Meyer,et al.  Role of P450IID6, the target of the sparteine‐debrisoquin oxidation polymorphism, in the metabolism of imipramine , 1991, Clinical pharmacology and therapeutics.

[62]  S. Sindrup,et al.  Role of genetic polymorphism in psychopharmacology--an update. , 1993, Psychopharmacology series.

[63]  M. Eastwood,et al.  NEUTROPHIL FUNCTION AND MYELOPEROXIDASE ACTIVITY IN INFLAMMATORY BOWEL DISEASE , 1976, The Lancet.

[64]  K. Brøsen,et al.  First‐pass metabolism of imipramine and desipramine: Impact of the sparteine oxidation phenotype , 1988, Clinical pharmacology and therapeutics.

[65]  P. Baumann,et al.  Dextromethorphan and Mephenytoin Phenotyping of Patients Treated with Thioridazine or Amitriptyline , 1992, Therapeutic drug monitoring.

[66]  E. Skjelbo,et al.  Fluoxetine and norfluoxetine are potent inhibitors of P450IID6--the source of the sparteine/debrisoquine oxidation polymorphism. , 1991, British journal of clinical pharmacology.

[67]  M. Eichelbaum,et al.  Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population. , 1998, Pharmacogenetics.

[68]  K. Otani,et al.  Is there a therapeutic window for plasma concentration of mianserin plus desmethylmianserin? , 1991 .

[69]  R. Haddock,et al.  Metabolic pathway of paroxetine in animals and man and the comparative pharmacological properties of its metabolites , 1989, Acta psychiatrica Scandinavica. Supplementum.

[70]  J. Azuma,et al.  The impact of the CYP2D6 and CYP2C19 genotypes on venlafaxine pharmacokinetics in a Japanese population , 2000, European Journal of Clinical Pharmacology.

[71]  E. Skjelbo,et al.  Inhibitors of imipramine metabolism by human liver microsomes. , 1992, British journal of clinical pharmacology.

[72]  S. Preskorn,et al.  Clinically Relevant Pharmacology of Selective Serotonin Reuptake Inhibitors , 1997, Clinical pharmacokinetics.

[73]  M. Dahl,et al.  Pharmacogenetic methods as a complement to therapeutic monitoring of antidepressants and neuroleptics. , 2000, Therapeutic drug monitoring.

[74]  P. Baumann,et al.  N-methylation of maprotiline in debrisoquine/mephenitoin-phenotyped depressive patients , 1985 .

[75]  J. Rapoport,et al.  Active metabolites of imipramine and desipramine in man , 1982, Clinical pharmacology and therapeutics.

[76]  R. Post,et al.  The emerging role of cytochrome P450 3A in psychopharmacology. , 1995, Journal of clinical psychopharmacology.

[77]  E. Hoencamp,et al.  Venlafaxine serum levels and CYP2D6 genotype. , 2000, Therapeutic drug monitoring.

[78]  Joe C. Watson,et al.  Report from the Second European Stroke Summer School, Heidelberg, Germany , 1999, Cerebrovascular Diseases.

[79]  E. Sellers,et al.  Venlafaxine oxidation in vitro is catalysed by CYP2D6. , 1996, British journal of clinical pharmacology.

[80]  K. Brøsen,et al.  Imipramine demethylation in vivo: Impact of CYP1A2, CYP2C19, and CYP3A4 , 1997, Clinical pharmacology and therapeutics.

[81]  R. Dahlqvist,et al.  Inhibition of desipramine 2‐hydroxylation by quinidine and quinine , 1988, Clinical pharmacology and therapeutics.

[82]  T. Someya,et al.  Metabolism of desipramine in Japanese psychiatric patients: the impact of CYP2D6 genotype on the hydroxylation of desipramine. , 2000, Pharmacology & toxicology.

[83]  L. Bertilsson,et al.  E‐ and Z‐10‐hydroxylation of nortriptyline: Relationship to polymorphic debrisoquine hydroxylation , 1981, Clinical pharmacology and therapeutics.

[84]  K. Brøsen,et al.  Pharmacokinetics of Citalopram in Relation to the Sparteine and the Mephenytoin Oxidation Polymorphisms , 1993, Therapeutic drug monitoring.

[85]  J. Hallas,et al.  The mephenytoin oxidation polymorphism is partially responsible for the N‐demethylation of imipramine , 1991, Clinical pharmacology and therapeutics.

[86]  F. Macciardi,et al.  Steady state concentrations of the enantiomers of mianserin and desmethylmianserin in poor and in homozygous and heterozygous extensive metabolizers of debrisoquine. , 1998, Therapeutic drug monitoring.

[87]  L. Bertilsson,et al.  CYP2C19 genotype and phenotype determined by omeprazole in a Korean population. , 1996, Pharmacogenetics.

[88]  Nonlinear pharmacokinetics of chlorimipramine after infusion and oral administration in patients , 1986, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[89]  M. Åsberg,et al.  Plasma levels of chlorimipramine and its demethyl metabolite during treatment of depression , 1979, Clinical pharmacology and therapeutics.

[90]  U. Gundert-Remy,et al.  Non-response to maprotiline caused by ultra-rapid metabolism that is different from CYP2D6? , 1997, European Journal of Clinical Pharmacology.

[91]  S. Tsuchida,et al.  Relationship between the CYP2D6 genotype and the steady-state plasma concentrations of trazodone and its active metabolite m-chlorophenylpiperazine , 1997, Psychopharmacology.

[92]  K. Otani,et al.  Inhibition of Trazodone Metabolism by Thioridazine in Humans , 1995, Therapeutic drug monitoring.

[93]  J. Hallas,et al.  The relationship between paroxetine and the sparteine oxidation polymorphism , 1992, Clinical pharmacology and therapeutics.

[94]  A. Fro̸land,et al.  Imipramine treatment of painful diabetic neuropathy. , 1984, JAMA.

[95]  K. Chiba,et al.  Identification of human cytochrome P450 isoforms involved in the stereoselective metabolism of mianserin enantiomers. , 1996, The Journal of pharmacology and experimental therapeutics.

[96]  B. Pollock,et al.  Antidepressants and drug‐metabolizing enzymes — expert group report , 1996, Acta psychiatrica Scandinavica.

[97]  L. Bertilsson,et al.  The debrisoquine hydroxylation test predicts steady-state plasma levels of desipramine. , 1983, British journal of clinical pharmacology.

[98]  T Ishizaki,et al.  Reappraisal of human CYP isoforms involved in imipramine N-demethylation and 2-hydroxylation: a study using microsomes obtained from putative extensive and poor metabolizers of S-mephenytoin and eleven recombinant human CYPs. , 1997, The Journal of pharmacology and experimental therapeutics.

[99]  B. Woggon,et al.  Importance of Oxidative Polymorphism on Clinical Efficacy and Side-Effects of Imipramine - A Retrospective Study , 1988, Pharmacopsychiatry.

[100]  C J Timmer,et al.  Clinical Pharmacokinetics of Mirtazapine , 2000, Clinical pharmacokinetics.

[101]  J. Turgeon,et al.  The disposition of fluoxetine but not sertraline is altered in poor metabolizers of debrisoquin , 1996, Clinical pharmacology and therapeutics.

[102]  T. Winkler,et al.  Isolation and identification of hydroxylated maprotiline metabolites. , 1985, Xenobiotica; the fate of foreign compounds in biological systems.

[103]  D. Wong,et al.  Norfluoxetine Enantiomers as Inhibitors of Serotonin Uptake in Rat Brain , 1993, Neuropsychopharmacology.

[104]  L. Ereshefsky.  Drug-Drug Interactions Involving Antidepressants: Focus on Venlafaxine , 1996, Journal of clinical psychopharmacology.

[105]  J. Goldstein,et al.  A multifamily study on the relationship between CYP2C19 genotype and s-mephenytoin oxidation phenotype. , 1995, Pharmacogenetics.

[106]  M. Ingelman-Sundberg,et al.  Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population , 1992, Clinical pharmacology and therapeutics.

[107]  L. Bertilsson,et al.  Amitriptyline metabolism: Relationship to polymorphic debrisoquine hydroxylation , 1983, Clinical pharmacology and therapeutics.

[108]  M. Åsberg,et al.  Monitoring Tricyclic Antidepressants , 1980, Therapeutic drug monitoring.

[109]  L. Bertilsson,et al.  Extremely rapid hydroxylation of debrisoquine: a case report with implication for treatment with nortriptyline and other tricyclic antidepressants. , 1985, Therapeutic drug monitoring.

[110]  K. Brøsen,et al.  The stereoselective metabolism of fluoxetine in poor and extensive metabolizers of sparteine. , 1999, Pharmacogenetics.

[111]  J. Miners,et al.  Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. , 1998, British journal of clinical pharmacology.

[112]  J. Azuma,et al.  Effect of the CYP2D6*10 genotype on venlafaxine pharmacokinetics in healthy adult volunteers. , 1999, British journal of clinical pharmacology.

[113]  L. Wienkers,et al.  Cytochrome P-450-mediated metabolism of the individual enantiomers of the antidepressant agent reboxetine in human liver microsomes. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[114]  J. Amsterdam,et al.  Fluoxetine and norfluoxetine plasma concentrations in major depression: a multicenter study. , 1997, The American journal of psychiatry.

[115]  J. de Leon,et al.  Pilot study of the cytochrome P450-2D6 genotype in a psychiatric state hospital. , 1998, The American journal of psychiatry.

[116]  B. Alexanderson,et al.  Steady-state plasma levels of nortriptyline in twins: Influence of genetic factors and drug therapy , 1969, British medical journal.

[117]  J. Hyttel.  Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs) , 1994, International clinical psychopharmacology.

[118]  E. Richelson.  Pharmacokinetic interactions of antidepressants. , 1998, The Journal of clinical psychiatry.

[119]  Interethnic dissociation between debrisoquine and desipramine hydroxylation. , 1985, Journal of clinical psychopharmacology.

[120]  U. Meyer,et al.  Identification of three cytochrome P450 isozymes involved in N-demethylation of citalopram enantiomers in human liver microsomes. , 1997, Pharmacogenetics.

[121]  C. Alm,et al.  Stereoselective disposition of mianserin is related to debrisoquin hydroxylation polymorphism , 1994, Clinical pharmacology and therapeutics.

[122]  J. T. Stewart,et al.  Quantitation of trimipramine enantiomers in human serum by enantioselective high-performance liquid chromatography and mixed-mode disc solid-phase extraction. , 1997, Journal of chromatography. B, Biomedical sciences and applications.

[123]  G. Granneman,et al.  Use of In Vitro and In Vivo Data to Estimate the Likelihood of Metabolic Pharmacokinetic Interactions , 1997, Clinical pharmacokinetics.

[124]  R. McAuley,et al.  Relationship between mianserin plasma levels and antidepressant effect in a double-blind trial comparing a single night-time and divided daily dose regimens. , 1978, British journal of clinical pharmacology.

[125]  C. Alm,et al.  In Vitro and In Vivo Studies on the Disposition of Mirtazapine in Humans , 1997 .

[126]  K. Brøsen,et al.  Single‐dose kinetics of clomipramine: Relationship to the sparteine and S‐mephenytoin oxidation polymorphisms , 1994, Clinical pharmacology and therapeutics.

[127]  T. Buclin,et al.  Influence of quinidine on the pharmacokinetics of trimipramine and on its effect on the waking EEG of healthy volunteers. A pilot study on two subjects. , 1992, Neuropsychobiology.

[128]  M. Eichelbaum,et al.  Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population. , 1991, DNA and cell biology.

[129]  B. Pollock,et al.  Bupropion plasma levels and CYP2D6 phenotype. , 1996, Therapeutic drug monitoring.

[130]  L. Gram.  Drug therapy : fluoxetine , 1994 .

[131]  Metabolism of trimipramine in vitro by human CYP2D6 isozyme. , 1993, Research communications in chemical pathology and pharmacology.

[132]  J. Heym,et al.  Comparison of the Effects of Sertraline and Its Metabolite Desmethylsertraline on Blockade of Central 5-HT Reuptake In Vivo , 1996, Neuropsychopharmacology.

[133]  M. Kosel,et al.  Ultrarapid metabolism of clomipramine in a therapy-resistant depressive patient, as confirmed by CYP2 D6 genotyping. , 1998, Pharmacopsychiatry.

[134]  K. Brøsen,et al.  Moclobemide, a substrate of CYP2C19 and an inhibitor of CYP2C19, CYP2D6, and CYP1A2: A panel study * , 1995, Clinical pharmacology and therapeutics.

[135]  S. Caccia.  Metabolism of the Newer Antidepressants , 1998, Clinical pharmacokinetics.

[136]  J S Harmatz,et al.  Inhibition of cytochrome P450 by nefazodone in vitro: studies of dextromethorphan O- and N-demethylation. , 2003, British journal of clinical pharmacology.

[137]  B. Woods,et al.  Maprotiline treatment in depression. A perspective on seizures. , 1986, Archives of general psychiatry.

[138]  S. Wrighton,et al.  Interaction of the enantiomers of fluoxetine and norfluoxetine with human liver cytochromes P450. , 1993, The Journal of pharmacology and experimental therapeutics.

[139]  L. Hollister.  Second-generation antidepressants. , 1982, Rational drug therapy.

[140]  K. Chiba,et al.  Steady-state plasma concentrations of imipramine and desipramine in relation to S-mephenytoin 4'-hydroxylation status in Japanese depressive patients. , 1996, Journal of clinical psychopharmacology.

[141]  D. H. Schroeder,et al.  Carbamazepine but not valproate induces bupropion metabolism. , 1995, Journal of clinical psychopharmacology.

[142]  Ö. Ericsson,et al.  Hydroxylation of desmethylimipramine: Dependence on the debrisoquin hydroxylation phenotype , 1987, Clinical pharmacology and therapeutics.

[143]  R. Barbhaiya,et al.  Single and multiple dose pharmacokinetics of nefazodone in subjects classified as extensive and poor metabolizers of dextromethorphan. , 1996, British journal of clinical pharmacology.

[144]  L. Bertilsson,et al.  CYP2C19 genotype and phenotype determined with omeprazole in patients with acid-related disorders with and without Helicobacter pylori infection. , 1998, Scandinavian journal of gastroenterology.

[145]  O. Olesen,et al.  Studies on the Stereoselective Metabolism of Citalopram by Human Liver Microsomes and cDNA-Expressed Cytochrome P450 Enzymes , 1999, Pharmacology.

[146]  T. Barnes,et al.  How to distinguish between the neuroleptic-induced deficit syndrome, depression and disease-related negative symptoms in schizophrenia , 1995, International clinical psychopharmacology.

[147]  K. Brøsen,et al.  Imipramine metabolism in relation to the sparteine and mephenytoin oxidation polymorphisms--a population study. , 1995, British journal of clinical pharmacology.

[148]  K. Brøsen.  Differences in interactions of SSRIs , 1998, International clinical psychopharmacology.

[149]  B. Testa,et al.  Determination of the enantiomers of citalopram, its demethylated and propionic acid metabolites in human plasma by chiral HPLC. , 1995, Chirality.

[150]  E. Spina,et al.  Urinary Desipramine Hydroxylation Index and Steady‐State Plasma Concentrations of Imipramine and Desipramine , 1987, Therapeutic drug monitoring.

[151]  L. Bertilsson,et al.  The CYP2D6 genotype and plasma concentrations of mianserin enantiomers in relation to therapeutic response to mianserin in depressed Japanese patients. , 1997, Journal of clinical psychopharmacology.

[152]  J. Turgeon,et al.  Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans. , 1999, Pharmacogenetics.

[153]  R. Fuller,et al.  Comparison of norfluoxetine enantiomers as serotonin uptake inhibitors in vivo , 1992, Neuropharmacology.

[154]  J. Turgeon,et al.  Involvement of CYP2D6 activity in the N-oxidation of procainamide in man. , 1999, Pharmacogenetics (London).

[155]  P. Baumann,et al.  Enantioselective amitriptyline metabolism in patients phenotyped for two cytochrome P450 isozymes , 1992, Clinical pharmacology and therapeutics.

[156]  L. Bertilsson,et al.  Nortriptyline and antipyrine clearance in relation to debrisoquine hydroxylation in man. , 1980, Life sciences.

[157]  O. Spigset,et al.  Seizures and myoclonus associated with antidepressant treatment: assessment of potential risk factors, including CYP2D6 and CYP2C19 polymorphisms, and treatment with CYP2D6 inhibitors , 1997, Acta psychiatrica Scandinavica.

[158]  P. Corey,et al.  Incidence of Adverse Drug Reactions in Hospitalized Patients , 2012 .

[159]  C. Gleiter,et al.  Maprotiline metabolism appears to co-segregate with the genetically-determined CYP2D6 polymorphic hydroxylation of debrisoquine. , 1994, British journal of clinical pharmacology.

[160]  U. Meyer,et al.  Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification , 1990, The Lancet.

[161]  Z. Kopitar,et al.  [Pharmacokinetics and metabolism of trazodone in man (author's transl)]. , 1976, Arzneimittel-Forschung.

[162]  K. Otani,et al.  Effects of various factors on steady state plasma concentrations of trazodone and its active metabolite m-chlorophenylpiperazine. , 1995, International clinical psychopharmacology.

[163]  K. Brøsen,et al.  Duplication of CYP2D6 predicts high clearance of desipramine but high clearance does not predict duplication of CYP2D6 , 2001, European Journal of Clinical Pharmacology.

[164]  K. Chiba,et al.  Effects of genetic defects in the CYP2C19 gene on the N‐demethylation of imipramine, and clinical outcome of imipramine therapy , 1997, Psychiatry and clinical neurosciences.

[165]  L. Bertilsson,et al.  Amitriptyline metabolism: Association with debrisoquin hydroxylation in nonsmokers , 1986, Clinical pharmacology and therapeutics.

[166]  C. Mazure,et al.  Antidepressant activity of 2‐hydroxydesipramine , 1988, Clinical pharmacology and therapeutics.